Artificial blood vessel as well as preparation method and application thereof

Abstract

The invention discloses an artificial blood vessel and a preparation method and application thereof, and relates to the technical field of artificial blood vessels, the artificial blood vessel comprises an artificial blood vessel stent material and a coating material at least partially coating the surface of the artificial blood vessel stent, and the coating material comprises a platelet coating, a GPIIb / IIIa receptor on the surface of a platelet membrane in the platelet coating is in a closed state. The platelet coating on the surface of the artificial blood vessel stent can promote recruitment, migration and proliferation of endothelial cells, so that the endothelialization process of the artificial blood vessel is accelerated; the GPIIb / IIIa receptor on the surface of the platelet membrane is in a closed state, so that the thrombus risk caused by platelets in the subsequent endothelialization process is avoided, and the blood coagulation function and the endothelialization function of the platelet coating are decoupled. The artificial blood vessel does not need additional chemical modification, the coating is biodegradable, and inflammation and foreign matter rejection phenomena caused by a traditional coating are avoided.

Description

Technical Field

[0001] The present invention relates to the technical field of artificial blood vessels, and in particular to an artificial blood vessel and a preparation method and application thereof. Background Art

[0002] Existing materials for making small-caliber artificial blood vessels can be divided into two categories: synthetic polymers such as polyester, expanded polytetrafluoroethylene, polyurethane, PGA, and PHA; and natural biomaterials such as collagen, hyaluronic acid, silk fibroin, chitosan, and bacterial cellulose. Large-caliber artificial blood vessels synthesized from these materials have achieved significant clinical success. However, when it comes to replacing small-caliber vessels with a diameter less than 6 mm, such as coronary arteries, existing base materials still cannot meet clinical needs due to issues such as clotting and long-term restenosis.

[0003] The key reason for this result is that small-caliber artificial blood vessels prepared with current materials lack endothelialization. In previous studies, implanting endothelial cells on the surface of small-caliber artificial blood vessels was considered an effective solution to achieve endothelialization. However, the reduced activity of endothelial cells after transplantation limits the effectiveness of this solution; another solution uses physical and chemical methods, such as controlling the surface morphology of small-caliber artificial blood vessels, loading growth factors, etc., to enhance the migration and adhesion of endothelial cells to achieve endothelialization of small-diameter artificial blood vessels. However, physical and chemical modifications cannot achieve the expected results. At the same time, before endothelialization of the blood vessels, the burst release of anticoagulants and the side effects of long-term use cannot be ignored. Summary of the Invention

[0004] The main purpose of the present invention is to provide an artificial blood vessel and its preparation method and application, aiming to solve the problem of lack of endothelialization in artificial blood vessels in the prior art.

[0005] To achieve the above-mentioned objectives, the present invention proposes an artificial blood vessel, which includes an artificial blood vessel stent and a coating that is at least partially coated on the surface of the artificial blood vessel stent, wherein the coating includes a platelet coating, and the GPIIb / IIIa receptors on the surface of the platelet membrane in the platelet coating are in a closed state.

[0006] In one embodiment, the platelet coating has a thickness of 10 to 20 μm; and / or,

[0007] The inner diameter of the artificial blood vessel is 2.0 to 4.0 mm; and / or,

[0008] The material of the artificial blood vessel stent includes polycaprolactone, polylactic acid or polyurethane.

[0009] In one embodiment, the GPIIb / IIIa receptor is in a blocked state comprising the GPIIb / IIIa receptor and an antagonist of the GPIIb / IIIa receptor.

[0010] In one embodiment, the antagonist comprises at least one of abciximab, eptifibatide, and tirofiban.

[0011] The present invention also provides a method for preparing an artificial blood vessel, comprising the following steps:

[0012] S10, obtaining an artificial vascular stent, and perfusing blood onto a surface of the artificial vascular stent so that the blood coagulates on the surface of the artificial vascular stent to form a coating, thereby obtaining an artificial vascular stent having a coating formed on the surface;

[0013] S20, immersing the artificial blood vessel stent with the coating formed on the surface in a solution containing a GPIIb / IIIa receptor antagonist, so that the GPIIb / IIIa receptors on the platelet membrane surface in the coating bind to the GPIIb / IIIa receptor antagonist and are blocked, thereby obtaining the artificial blood vessel.

[0014] In one embodiment, in step S10, the method for obtaining an artificial vascular stent comprises preparing the artificial vascular stent by electrospinning an organic solution containing an artificial vascular stent material:

[0015] Add 15 g of artificial vascular stent material to every 100 mL of organic solvent; and / or,

[0016] The injection speed of the electrospinning is 0.2 to 0.4 mm / min; and / or,

[0017] The applied voltage of the electrospinning is 5.5 to 7.5 V; and / or,

[0018] The rotation speed of the receiver in the electrospinning is 25 to 35 r / min; and / or,

[0019] The electrospinning time is 60 to 80 minutes.

[0020] In one embodiment, in step S10, 10 to 15 mL of blood is perfused per 6 cm of an artificial vascular stent with an inner diameter of 2 mm.

[0021] In one embodiment, in step S10, the perfusion includes placing the artificial blood vessel stent in a catheter and performing circulatory perfusion via a pump:

[0022] The circulatory perfusion time is 0.5 to 2 hours, and the catheter is pre-soaked in an anticoagulant for 20 to 40 minutes.

[0023] In one embodiment, in step S20:

[0024] The concentration of the GPIIb / IIIa receptor antagonist in the solution containing the GPIIb / IIIa receptor antagonist is 8 to 12 μg / mL; and / or,

[0025] The soaking time is 0.4 to 0.6 hours.

[0026] The present invention also provides an application of an artificial blood vessel in preparing a vascular patch. The artificial blood vessel includes the aforementioned artificial blood vessel or an artificial blood vessel prepared by the aforementioned method for preparing an artificial blood vessel.

[0027] The technical solution of the present invention innovatively proposes an artificial blood vessel structure based on the platelet's own coagulation mechanism. The platelet coating on the surface of the artificial blood vessel stent can promote the recruitment, migration and proliferation of endothelial cells, thereby accelerating the endothelialization process of the artificial blood vessel. At the same time, the GPIIb / IIIa receptors on the surface of the platelet membrane in the platelet coating are in a closed state, that is, the receptors cannot bind to fibrinogen to mediate aggregation between platelets, avoiding the risk of platelet-induced thrombosis during the subsequent endothelialization process, and achieving the decoupling of the coagulation function and endothelialization function of the platelet coating. The artificial blood vessel of the present invention does not require additional chemical modification, the coating is biodegradable, and it avoids the inflammation and foreign body rejection caused by traditional coatings. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying any creative work.

[0029] Figure 1 (a) is the preparation process of electrospinning in Example 1 of the present invention; Figure 1 (b) is a diagram showing the process of circulating blood into the artificial vascular stent and the mechanism of the platelet coating after being sealed in Example 1 of the present invention;

[0030] Figure 2 This is a graph showing the coagulation ability results of the artificial blood vessel with active coating prepared in Example 1 of the present invention and the artificial blood vessel without active coating prepared in Comparative Example 1;

[0031] Figure 3 This is a graph showing the endothelialization progress of the artificial blood vessel with active coating prepared in Example 1 of the present invention and the artificial blood vessel without active coating prepared in Comparative Example 1.

[0032] The purpose, features and advantages of the present invention will be further described with reference to the accompanying drawings and in conjunction with the embodiments. DETAILED DESCRIPTION

[0033] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or the conditions recommended by the manufacturer. Where the reagents or instruments used are not specified by the manufacturer, they are all conventional products that can be purchased commercially. In addition, the meaning of "and / or" appearing in the full text includes three parallel schemes. Taking "A and / or B" as an example, it includes scheme A, or scheme B, or schemes that A and B meet at the same time. In addition, the technical solutions between the various embodiments can be combined with each other, but must be based on the ability of ordinary technicians in this field to achieve. When the combination of technical solutions is contradictory or cannot be achieved, it should be considered that the combination of such technical solutions does not exist and is not within the scope of protection required by the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0034] Existing materials for making small-caliber artificial blood vessels can be divided into two categories: synthetic polymers such as polyester, expanded polytetrafluoroethylene, polyurethane, PGA, and PHA; and natural biomaterials such as collagen, hyaluronic acid, silk fibroin, chitosan, and bacterial cellulose. Large-caliber artificial blood vessels synthesized from these materials have achieved significant clinical success. However, when it comes to replacing small-caliber vessels with a diameter less than 6 mm, such as coronary arteries, existing base materials still cannot meet clinical needs due to issues such as clotting and long-term restenosis.

[0035] The key reason for this result is that small-caliber artificial blood vessels prepared with current materials lack endothelialization. In previous studies, implanting endothelial cells on the surface of small-caliber artificial blood vessels was considered an effective solution to achieve endothelialization. However, the reduced activity of endothelial cells after transplantation limits the effectiveness of this solution; another solution uses physical and chemical methods, such as controlling the surface morphology of small-caliber artificial blood vessels, loading growth factors, etc., to enhance the migration and adhesion of endothelial cells to achieve endothelialization of small-diameter artificial blood vessels. However, physical and chemical modifications cannot achieve the expected results. At the same time, before endothelialization of the blood vessels, the burst release of anticoagulants and the side effects of long-term use cannot be ignored.

[0036] In view of this, the present invention provides an artificial blood vessel, which includes an artificial blood vessel stent and a coating that is at least partially coated on the surface of the artificial blood vessel stent, wherein the coating includes a platelet coating, and the GPIIb / IIIa receptors on the surface of the platelet membrane in the platelet coating are in a closed state.

[0037] In the technical solution of the present invention, an artificial blood vessel structure is innovatively proposed based on the platelet's own coagulation mechanism. The platelet coating on the surface of the artificial blood vessel stent can promote the recruitment, migration and proliferation of endothelial cells, thereby accelerating the endothelialization process of the artificial blood vessel. At the same time, the GPIIb / IIIa receptors on the surface of the platelet membrane in the platelet coating are in a closed state, that is, the receptors cannot bind to fibrinogen to mediate aggregation between platelets, avoiding the risk of platelet-induced thrombosis in the subsequent endothelialization process, and realizing the decoupling of the coagulation function and endothelialization function of the platelet coating. The artificial blood vessel of the present invention does not require additional chemical modification, the coating is biodegradable, and the inflammation and foreign body rejection caused by traditional coatings are avoided.

[0038] Understandably, when blood vessels function normally, endothelial cells often have a natural anticoagulant effect, preventing platelets from being activated to perform their coagulation function. However, after vascular damage, a natural repair mechanism occurs. Specifically, platelets first rapidly aggregate at the site of injury, forming thrombi for initial hemostasis. Simultaneously, they release multiple growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF), to promote endothelial cell repair. Platelets and other components in isolated blood still perform their coagulation function.

[0039] In some embodiments, the platelet coating has a thickness of 10 to 20 μm. It is understood that a platelet coating thickness within the above range can ensure that the surface of the artificial vascular stent has sufficient platelets to promote endothelial cell adhesion.

[0040] In some embodiments, the artificial blood vessel has an inner diameter of 2.0 to 4.0 mm. In some embodiments, the artificial blood vessel is made of polycaprolactone, polylactic acid, or polyurethane. It is understood that the selection of these materials can ensure that the artificial blood vessel stent has good biocompatibility, sufficient mechanical properties to adapt to the dynamic environment of the human body, and can withstand blood pressure fluctuations without rupture or excessive expansion.

[0041] In some embodiments, the GPIIb / IIIa receptor is in a blocked state, including binding of the GPIIb / IIIa receptor to an antagonist of the GPIIb / IIIa receptor. When the GPIIb / IIIa receptor is bound to the antagonist, the GPIIb / IIIa receptor is in a blocked state, meaning that it cannot bind to fibrinogen or other ligands, thereby preventing platelet aggregation and subsequent thrombosis.

[0042] In some embodiments, the antagonist includes at least one of abciximab, eptifibatide, and tirofiban. It is understood that the antagonist can be any one of abciximab, eptifibatide, and tirofiban, or two or three of abciximab, eptifibatide, and tirofiban, all within the scope of protection of the present invention. Among them, abciximab is a monoclonal antibody fragment that can specifically bind to the GPIIb / IIIa receptor and effectively inhibit platelet aggregation; eptifibatide is a cyclic heptapeptide that competitively binds to the GPIIb / IIIa receptor and prevents fibrinogen from binding to it; tirofiban is a small molecule non-peptide inhibitor that works by selectively blocking the interaction between the GPIIb / IIIa receptor and fibrinogen. The above antagonists can all bind to the GPIIb / IIIa receptor relatively quickly to block it. Preferably, the antagonist is abciximab, which is irreversible in its binding to the GPIIb / IIIa receptor and has good stability.

[0043] The present invention also provides a method for preparing an artificial blood vessel, comprising the following steps: S10, obtaining an artificial blood vessel stent, perfusing blood onto the surface of the artificial blood vessel stent so that the blood coagulates on the surface of the artificial blood vessel stent to form a coating, thereby obtaining an artificial blood vessel stent with a coated surface; S20, immersing the artificial blood vessel stent with a coated surface in a solution containing a GPIIb / IIIa receptor antagonist so that the GPIIb / IIIa receptors on the surface of the platelet membrane in the coating bind to the GPIIb / IIIa receptor antagonist and are blocked, thereby obtaining the artificial blood vessel.

[0044] The technical solution of the present invention innovatively proposes a coating modification strategy based on the platelet's own coagulation mechanism. Specifically, blood circulation is perfused into the surface of the artificial vascular stent, including the inner and outer surfaces. When the platelets in the blood come into contact with the artificial vascular stent without endothelial cells, they are activated and, together with other components in the blood, quickly form a coagulated coating on the surface of the artificial vascular stent, thereby obtaining an artificial vascular stent with a coated surface. Subsequently, the stent is immersed in a solution containing a GPIIb / IIIa receptor antagonist, so that the GPIIb / IIIa receptors on the surface of the platelets in the coating quickly bind to the antagonist and are blocked, thereby achieving the decoupling of platelet-mediated coagulation and endothelialization function, and obtaining an artificial blood vessel. This strategy can not only promote endothelial cell adhesion, migration and proliferation, accelerate the endothelialization process, but also effectively reduce the risk of thrombosis.

[0045] It is understood that the blood used for perfusion can be fresh blood collected from a blood collection tube containing an anticoagulant such as sodium citrate aqueous solution, sodium heparin aqueous solution, or ethylenediaminetetraacetic acid aqueous solution, wherein the volume ratio of anticoagulant to blood is 1:9, and the anticoagulant concentration can be 100 IU / mL. It should be noted that due to the low anticoagulant content, the fresh blood does not affect blood coagulation on the surface of the artificial blood vessel during perfusion.

[0046] The method of the present invention is characterized by low cost and high biocompatibility. It does not require complex chemical modification, allows for rapid coating construction, and significantly reduces production costs. It also avoids the inflammatory response associated with long-term in vivo retention of traditional coatings. Furthermore, the perfused blood used to construct the coating can be derived from the patient's own body, significantly reducing immunogenicity.

[0047] In some embodiments, in step S10, the method for obtaining an artificial vascular stent includes preparing the artificial vascular stent by electrospinning an organic solution containing an artificial vascular stent material: 15 g of the artificial vascular stent material is added to every 100 mL of organic solvent; and / or the injection speed of the electrospinning is 0.2 to 0.4 mm / min; and / or the applied voltage of the electrospinning is 5.5 to 7.5 V; and / or the rotation speed of the receiver during the electrospinning is 25 to 35 rpm; and / or the electrospinning time is 60 to 80 minutes. It is understood that simultaneously controlling the raw material ratio, injection speed, applied voltage, receiver rotation speed, and time of electrospinning within the above ranges can ensure high quality of the artificial blood vessel and good fiber uniformity.

[0048] In some embodiments, in step S10, 10-15 mL of blood containing an anticoagulant is perfused per 6 cm of an artificial blood vessel stent with an inner diameter of 2 mm. The ratio of the artificial blood vessel length to the blood is within the above range, which can ensure that the surface of the artificial blood vessel stent has a more uniform and sufficient platelet coating.

[0049] In some embodiments, in step S10, the perfusion includes placing the artificial vascular stent in a catheter and performing circulatory perfusion via a pump. The circulatory perfusion duration is 0.5 to 2 hours, and the catheter is pre-soaked in an anticoagulant for 20 to 40 minutes. The circulatory perfusion duration can be 0.5 hours, 1 hour, or 2 hours. A circulatory perfusion duration within this range ensures that a relatively uniform platelet coating of an appropriate thickness is formed on the surface of the artificial vascular stent. The purpose of pre-soaking the catheter in an anticoagulant is to prevent blood in the catheter from clotting during circulation.

[0050] In some embodiments, in step S20, the concentration of the GPIIb / IIIa receptor antagonist in the solution containing the GPIIb / IIIa receptor antagonist is 8 to 12 μg / mL; and / or the soaking time is 0.4 to 0.6 hours. Soaking the artificial vascular stent with a coating formed on its surface in the solution containing the GPIIb / IIIa receptor antagonist for a time within the above range can ensure that the GPIIb / IIIa receptors in the platelet coating on the surface of the artificial vascular stent are quickly and fully bound to the antagonist and blocked, thereby quickly achieving decoupling of the coagulation function and endothelialization function of the platelet coating.

[0051] The present invention further provides an artificial blood vessel for use in preparing a vascular patch. The artificial blood vessel comprises the aforementioned artificial blood vessel or an artificial blood vessel prepared by the aforementioned method for preparing an artificial blood vessel. Therefore, the artificial blood vessel has all the beneficial effects of the aforementioned artificial blood vessel or method for preparing an artificial blood vessel, and no further details are given here.

[0052] The technical solutions of the present invention are further described in detail below in conjunction with specific embodiments and drawings. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.

[0053] Example 1

[0054] An artificial blood vessel is prepared by the following steps:

[0055] (1) Construction of small-caliber artificial vascular stents: Figure 1 As shown in (a), polycaprolactone (number-average molecular weight 80,000) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol to prepare a 15% (w / v) electrospinning solution. Subsequently, the electrospinning solution was loaded into a 5mL syringe using a 21-gauge needle and injected using a syringe pump at a speed of 0.3 mm / min and an applied voltage of 6.5 kV. The receiver was a 2mm-diameter stainless steel rod rotating at 30 rpm. After 70 minutes, a 6cm-long small-diameter artificial vascular stent was removed from the stainless steel rod.

[0056] (2) Extracorporeal blood perfusion of small-caliber artificial blood vessels: Figure 1 As shown in (b), an extracorporeal circulation system is constructed by connecting a peristaltic pump, a catheter pre-soaked in a 100 IU / mL sodium heparin aqueous solution (anticoagulant) for 30 minutes, and a beaker. A small-caliber artificial blood vessel is placed inside the catheter and secured. 5 mL of rabbit blood is collected and poured into the beaker of the extracorporeal circulation system. The peristaltic pump is turned on to pump the rabbit blood in the beaker through the catheter to the small-caliber artificial blood vessel. The blood is continuously circulated through the small-caliber artificial blood vessel for 1 hour, resulting in a small-caliber artificial blood vessel with a platelet coating.

[0057] (3) Blocking effect of anticoagulant drugs on coagulation sites of platelet coating: GPIIb / IIIa receptor antagonist abciximab was selected, and a 10 μg / mL abciximab solution was prepared with phosphate buffered saline (PBS). The small-caliber artificial blood vessel with platelet coating prepared in step (2) was immersed in the abciximab solution for 0.5 h, taken out, and freeze-dried to obtain an artificial blood vessel with an active coating.

[0058] Comparative Example 1

[0059] Comparative Example 1 is different from Example 1 in that:

[0060] Steps (2) and (3) are not performed.

[0061] Comparative Example 2

[0062] Comparative Example 2 is different from Example 1 in that:

[0063] Step (3) is not performed.

[0064] Performance Testing

[0065] The coagulation ability test of the artificial blood vessels prepared in Example 1 and Comparative Example 1 was carried out. The test method was as follows: the artificial blood vessels were connected to the extracorporeal circulation system, and plasma without anticoagulant was perfused. After 30 minutes, the artificial blood vessels were taken out and the coagulation situation on the surface of the artificial blood vessels was observed. The results were as follows: Figure 2 shown.

[0066] Depend on Figure 2 It can be seen that the active sites of the artificial blood vessel in Example 1 have the ability to inhibit blood coagulation after being blocked, and basically no blood coagulates on its surface, thereby avoiding the risk of local thrombosis.

[0067] The artificial blood vessels prepared in Example 1 and Comparative Example 1 were subjected to endothelialization testing. The testing method was as follows: 5000 endothelial cells were planted on the surface of the artificial blood vessels. After 24 hours, the cells were stained with a nuclear dye. The stained cells were observed under a confocal microscope and the cell number was counted. The results were as follows: Figure 3 shown.

[0068] Depend on Figure 3 It can be seen that the endothelialization process of the artificial blood vessel prepared in Example 1 is faster, which indicates that the platelet activation layer promotes the adhesion speed of endothelial cells on the artificial blood vessel.

[0069] The above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Those skilled in the art will readily appreciate that the present invention is susceptible to various modifications and variations. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention shall be included within the scope of the present invention.

Claims

1. An artificial blood vessel, characterized in that: The artificial blood vessel includes an artificial blood vessel stent and a coating at least partially covering the surface of the artificial blood vessel stent. The coating includes a platelet coating, and the GPIIb / IIIa receptors on the surface of the platelet membrane in the platelet coating are in a closed state.

2. The artificial blood vessel according to claim 1, wherein The thickness of the platelet coating is 10 to 20 μm; and / or, The inner diameter of the artificial blood vessel is 2.0 to 4.0 mm; and / or, The material of the artificial blood vessel stent includes polycaprolactone, polylactic acid or polyurethane.

3. The artificial blood vessel according to claim 1, wherein: The GPIIb / IIIa receptor being in a closed state includes the GPIIb / IIIa receptor being bound to an antagonist of the GPIIb / IIIa receptor.

4. The artificial blood vessel according to claim 3, wherein: The antagonist comprises at least one of abciximab, eptifibatide, and tirofiban.

5. A method for preparing an artificial blood vessel according to any one of claims 1 to 4, characterized in that: The following steps are involved: S10, obtaining an artificial vascular stent, and perfusing blood onto a surface of the artificial vascular stent so that the blood coagulates on the surface of the artificial vascular stent to form a coating, thereby obtaining an artificial vascular stent having a coating formed on the surface; S20, immersing the artificial blood vessel stent with the coating formed on the surface in a solution containing a GPIIb / IIIa receptor antagonist, so that the GPIIb / IIIa receptors on the platelet membrane surface in the coating bind to the GPIIb / IIIa receptor antagonist and are blocked, thereby obtaining the artificial blood vessel.

6. The method for preparing an artificial blood vessel according to claim 5, wherein: In step S10: the method for obtaining an artificial vascular stent comprises preparing an artificial vascular stent by electrospinning an organic solution containing an artificial vascular stent material: Add 15 g of artificial vascular stent material to every 100 mL of organic solvent; and / or, The injection speed of the electrospinning is 0.2 to 0.4 mm / min; and / or, The applied voltage of the electrospinning is 5.5 to 7.5 V; and / or, The rotation speed of the receiver in the electrospinning is 25 to 35 r / min; and / or, The electrospinning time is 60 to 80 minutes.

7. The method for preparing an artificial blood vessel according to claim 5, wherein: In step S10, 10 to 15 mL of blood is perfused into each 6 cm long artificial blood vessel stent with an inner diameter of 2 mm.

8. The method for preparing an artificial blood vessel according to claim 5, wherein: In step S10, the perfusion includes placing the artificial blood vessel stent in a catheter and performing circulatory perfusion by a pump: The circulatory perfusion time is 0.5 to 2 hours, and the catheter is pre-soaked in an anticoagulant for 20 to 40 minutes.

9. The method for preparing an artificial blood vessel according to claim 5, wherein: In step S20: The concentration of the GPIIb / IIIa receptor antagonist in the solution containing the GPIIb / IIIa receptor antagonist is 8 to 12 μg / mL; and / or, The soaking time is 0.4 to 0.6 hours.

10. Use of an artificial blood vessel in preparing a vascular patch, characterized in that: The artificial blood vessel includes the artificial blood vessel according to any one of claims 1 to 4 or an artificial blood vessel prepared by the method for preparing an artificial blood vessel according to any one of claims 5 to 9.

Images